Neoadjuvant chemotherapy (NAC) was initially used to treat patients with locally advanced breast cancer, but its use has expanded to early-stage breast cancer, especially those with high-risk early-stage breast cancer, such as triple-negative, HER2-positive, and axillary node-positive of breast cancer patients [2–4]. Here, ERBB2 is linked to breast cancer.